Annual report pursuant to Section 13 and 15(d)

7. Subsequent Events

v3.20.4
7. Subsequent Events
12 Months Ended
Dec. 31, 2020
Subsequent Events [Abstract]  
Subsequent Events

Note 7 – Subsequent Events

  

Subsequent to December 31, 2020, the Company received $332,750 in cash proceeds from the exercise of 151,250 warrants previously issued at an exercise price of $2.20. In addition, the Company received notices to exercise 1,580,140 warrants on a cashless basis resulting in issuance of 1,293,467 shares of common stock.

 

Subsequent to December 31, 2020, the Company entered into a transaction with HPI, a related party, to supply starting materials for the manufacturing of Berubicin API valued at $385,000.